九洲药业子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)

Group 1 - The core point of the article is that Jiuzhou Pharmaceutical (603456.SH) announced its full subsidiary, Hongzhou Investment, plans to invest in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) [1] - The total subscribed capital of the partnership is 77 million yuan, and Hongzhou Investment will contribute 10 million yuan, accounting for 12.987% of the total subscribed capital [1] - The investment direction of the partnership focuses on new drug research and development, medical device research and development, and other pharmaceutical-related fields, including emerging medical enterprises such as new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing R&D companies [1]